Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Jeollanam-do
Clinical trial register · South Korea

Clinical Trials in Jeollanam-do, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Jeollanam-do

34 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Jeollanam-do, Seoul
2026-02-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Jeollanam-do, Yangsan, Busan, Daejeon, Seoul
2025-10-08
Recruiting
Yuhan Corporation
Phase 3
60
Gyeonggi-do, Jeollanam-do, Jeollabuk-do, Seoul
2024-12-04
Active, closed
Hoffmann-La Roche
Phase 3
338
Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2024-09-23
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Chungcheongbuk Do, Gyeonggi-do, Jeollanam-do, Seoul
2024-04-18
Recruiting
International Extranodal Lymphoma Study Group (IELSG)
Observational
300
Jeollanam-do
2024-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Chungcheongbuk Do, Daegu, Gyeonggi-do, Jeollanam-do, Seoul, Yangsan
2024-04-09
Recruiting
Astellas Pharma Korea, Inc.
Observational
202
Goyang-si, Suwon, Jeollanam-do, Jeonju, Busan, Daegu, Daejeon, Incheon
2023-11-01
Active, closed
Hoffmann-La Roche
Phase 3
687
Goyang-si, Gyeonggi-do, Jeollanam-do, Seoul, Ulsan
2023-09-14
Active, closed
Janssen Research & Development, LLC
Phase 2
68
Cheongju-si, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2023-05-18
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Busan, Cheongju-si, Daegu, Gyeonggi-do, Jeollanam-do, Seoul
2023-03-23
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Cheongju-si, Goyang-si, Incheon, Jeollanam-do, Seongnam, Seoul
2022-12-13
Active, closed
Hoffmann-La Roche
Phase 3
68
Daegu, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2022-11-01
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Gyeonggi-do, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2022-08-05
Recruiting
Hoffmann-La Roche
Phase 1
542
Goyang-si, Jeollanam-do, Seongnam-si, Seoul
2021-10-22
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Jeollanam-do, Seoul
2021-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Busan, Gyeonggi-do, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2020-10-13
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
507
Daegu, Goyang-si, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seongnam-si, Seoul
2018-11-28
Active, closed
Hoffmann-La Roche
Phase 3
257
Gyeonggi-do, Incheon, Jeollanam-do, Seoul
2018-08-16
Active, closed
Bristol-Myers Squibb
Phase 3
545
Suwon, Seoul, Daegu, Goyang-si, Gyeongsangnam-do, Jeollanam-do, Seongnam-si
2018-04-18
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Gyeonggi-do, Jeollanam-do, Seoul
2017-09-22
Active, closed
Hoffmann-La Roche
Phase 3
382
Gyeonggi-do, Jeollanam-do, Seoul
2017-09-20
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Daegu, Daejeon, Goyang-si, Jeollanam-do, Seongnam-si, Seoul
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Buk Gu, Gyeonggi-do, Jeollanam-do, Seoul, Suwon
2015-11-19
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/jeollanam-do

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Jeollanam-do.

How many clinical trials are recruiting in Jeollanam-do?

10 of the 34 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 24 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jeollanam-do), 34 studies
PhaseStudiesRecruitingShare
Phase 325673.5%
Phase 24111.8%
Observational225.9%
Phase 1112.9%
Phase 1/2102.9%
Phase 2/3102.9%

Most active sponsors

Lead sponsors with the most studies (Jeollanam-do)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC132
Hoffmann-La Roche113
Aragon Pharmaceuticals, Inc.20
Merck Sharp & Dohme LLC21
Astellas Pharma Global Development, Inc.10
Astellas Pharma Korea, Inc.11
Bristol-Myers Squibb10
International Extranodal Lymphoma Study Group (IELSG)11
LeonaBio11
Yuhan Corporation11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.